Biogen recently named Christopher Viehbacher its new CEO, ending a monthslong search to replace Michel Vounatsos. Fraiser Kansteiner and Kevin Dunleavy talk about the current state of the company and recent investor reactions to the new hire. Plus, they discuss a string of other biopharma CEO appointments. 

And, in this episode, we cover the week's news including what Albert Bourla, Ph.D., said that has him in hot water along with a $3.5 million drug, and we tease a possible major acquisition. 

To learn more about topics in this episode:

• Biogen's incoming CEO Viehbacher gets mixed reviews—and lots of advice—in investor survey 
• Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line 
• Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal 
• Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths
• Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A 
• Pfizer CEO Bourla stung by UK's pharma marketing regulator over kids' COVID vax claims: report 
• GE Healthcare unveils AI program bundle for simplified MRI scans
• Philips unveils AI-powered platform to improve diagnoses from imaging scans

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.